A list of commonly used measurement tools for psoriasis management and clinical trials.
General
A simple 10-question validated questionnaire that has been used in over 40 different skin conditions in over 80 countries and is available in over 90 languages to measure disease severity and quality of life.
To express the severity of psoriasis by measuring redness, thickness, and scaliness of the lesions, weighed by the area of involvement.
PGA: Physician's Global Assessment
Physician's assessment of the severity of disease based on a scale from clear to very severe.
Self-administered, patient-reported outcome measure (PRO) to assess symptom severity in chronic, plaque psoriasis.
A 10-question questionnaire based on the experiences of children with skin disease. Available in both a text-only version as well as The Cartoon CDLQI, with each question illustrated by a cartoon based on the theme of the question, catering to younger children.
PEST is a validated screening tool for psoriatic arthritis (PsA) and it is recommended that patients with psoriasis who do not have a diagnosis of PsA complete an annual PEST questionnaire (NICE psoriasis guidelines 2012). A score of 3 or more indicates referral to rheumatology should be considered.
A clinical outcome measure for the assessment of genital psoriasis severity that accounts for the erythematous clinical presentation of genital psoriasis
IPC does not endorse or accept any responsibility for the content of external websites.
congress coverage SID 2021 Read the psoriasis highlights from the SID 2021 congress learn more
Latest news PsoProtect Registry Data UpdateSeptember 13, 2021Update on the PsoProtect Registry. PsoProtect is a global registry for clinicians to report outcomes of COVID-19 in individuals with psoriasis. Data set currently includes 1,205 cases. July Update on PsoProtect Registry DataJuly 12, 2021Update on the PsoProtect Registry. PsoProtect is a global registry for clinicians to report outcomes of COVID-19 in individuals with psoriasis. Data set currently includes 1,147 cases. Expert Opinion: Coronavirus disease 2019 (COVID‐19)‐associated hospitalization and mortality in patients with psoriasis: A population‐based studyJuly 07, 2021IPC Councilor, Luigi Naldi, MD, shares his expert opinion on a population-based study of COVID-19 - associated hospitalization and mortality in patients with psoriasis. Grand Rounds tutorial on IPC's psoriasis severity reclassificationJune 21, 2021The AbbVie program features IPC Board Member Bruce Strober’s Grand Rounds, a tutorial explaining the current method of measuring the severity of psoriasis, why this limits proper care and treatment for psoriasis patients, how IPC’s Disease Severity Reclassification Project solves these problems, and how clinicians can implement this new classification method. More News